Foamix Pharmaceuticals names new CEO

Foamix Pharmaceuticals Ltd. recently announced that its board of directors has named David Domzalski as CEO, effective immediately.

Domzalski succeeds Dov Tamarkin, PhD, as CEO. Tamarkin, co-founder of Foamix, will continue to serve on the board of directors and will serve as chief scientific advisor, according to a news release.

Domzalski, with 25 years of experience in the pharmaceutical industry, joined Foamix in 2014. He has served for the past three years as president of Foamix Pharmaceuticals Inc., the company’s U.S. subsidiary. He has been involved in the advancement of two late-stage clinical development programs, FMX101 for moderate-to-severe acne and FMX103 for moderate-to-severe papulopustular rosacea, both of which are currently in phase 3, according to the release.

Foamix also announced that Meir Eini will step down from his role of chief innovation officer, but will continue to serve as an innovation adviser for Foamix.

Ilan Hadar, the current chief financial officer of Foamix, has been named country manager in Israel, in addition to his role as chief financial officer, according to the release.

Tamarkin and Eini are co-founders of the specialty pharmaceutical company focused on the development and commercialization of proprietary topical drugs for dermatological therapy.

Reference: www.foamixpharma.com